Stock Analysis of BELLUS Health Inc. (BLU) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BLU
Close 14.74
Change 0 / 0 %
Volume 3378.81 K
Vol Change 2946.89 K / 682.26 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of BELLUS Health Inc.
PE (TTM)

-20.46

Very Poor
Price / Book

5.19

Very Poor
Price / Sales

118364

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

1869.21 M

Enterprise Value

1782.31 M

ROA (TTM)

-24.15

Very Poor
ROE (TTM)

-25.37

Very Poor
Net Margin (TTM)

-578586.67

Very Poor
Revenue

0 %

16000.00
Net Profit

6.82 %

-76080.00 K
Debt to Equity

0.0009

Excellent
Altman Z Score

64.93

Excellent
Quick Ratio

0

Poor
Cash Ratio

21.23

Excellent


Highs/Lows of BELLUS Health Inc.
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week14.72 0.136 % 0.513 % 14.7614.7126-Jun-2322-Jun-23
Two Week14.55 1.31 % 0.486 % 14.7614.3926-Jun-2315-Jun-23
One Month14.56 1.24 % 4.80 % 14.7614.3926-Jun-2315-Jun-23
Three Month7.14 106.44 % 3.56 % 14.766.3826-Jun-2305-Apr-23
Six Months8.35 76.53 % 15.54 % 14.766.3826-Jun-2305-Apr-23
One year9.38 57.14 % 26.26 % 14.766.3826-Jun-2305-Apr-23
Two year3.28 349.39 % 27.72 % 14.764.9826-Jun-2324-Jan-22
Five year1.4688 903.54 % 91.77 % 14.761.4396426-Jun-2305-Jul-18
Ten year0.90864 1522.20 % 174.36 % 14.760.6022826-Jun-2325-Jul-16


Technical View of BELLUS Health Inc.
RSI

78.88

Mild Bearish
MACD

0.211

Strong Bearish
ADX

51.09

Bullish
Super Trend

14.59

Mild Bullish
Williams %R

-5.41

Mild Bearish
CCI

98.70

Strong Bearish


EMA 5

14.73

Bullish
EMA 15

14.67

Bullish
EMA 50

13.64

Bullish
EMA 100

12.14

Bullish
SMA 100

11.04

Bullish
SMA 200

10.13

Bullish
SMA 5 / 20

14.74 / 14.64

Mild Bullish
SMA 15 / 50

14.65 / 14.55

Bullish
SMA 50 / 200

14.55 / 10.13

Strong Bullish




Charts of BELLUS Health Inc.


Returns of BELLUS Health Inc. with Peers
Period / StockBLUTDOCADUSGLPG
1 Week0.136%-2.09%2.87%2.02%
1 Mth1.24%-11.84%19.41%-2.21%
3 Mth106.44%-25.46%24.41%-20.76%
6mth76.53%-38.04%31.66%-25.67%
1 Year57.14%-51.45%27.35%-32.74%
2 Year349.39%-67.03%37.50%-49.43%
5 Years903.54%-80.66%67.90%-75.52%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of BELLUS Health Inc. with Peers
Ratio / StockBLUTDOCADUSGLPG
PE-20.46-4006.2628.528.65
P/B5.19406.072.730.681
ROA-24.15-5.386.664.75
ROE-25.37-10.149.577.87
Debt To Equity0.00090.6660.1920.0017
Revenue16000.00
0 % 		2579.60 M
7.18 % 		1029.35 M
8.23 % 		543968 K
7.66 %
Net Income-76080.00 K
6.82 % 		-4001.55 M
70.71 % 		57700.00 K
25.37 % 		-153069.00 K
29.78 %


Technicals of BELLUS Health Inc. with Peers
Technical / StockBLUTDOCADUSGLPG-
ADX51.0928.3536.2221.77
CMF0.310-0.1850.258-0.304
MFI47.3226.7572.4245.44
RSI78.8831.1172.6039.75
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MATrueFalseTrueFalse-
Price Above 200 MATrueFalseTrueFalse-


About : BELLUS Health Inc.

Address : 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7
Tel : 450 680 4500
URL : https://www.bellushealth.com
Code : BLU, ISIN : CA07987C2040, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 29_Dec_2008
Employee Count : 74

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.


Note : All Data Generated at the End of Trading Hours (EOD Data)